Suggested remit: To appraise the clinical and cost effectiveness of zilucoplan within its marketing authorisation for treating antibody-positive generalised myasthenia gravis.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 4008

Provisional Schedule

Committee meeting 13 June 2024
Expected publication 07 August 2024

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Stakeholders

Companies sponsors UCB Pharma (Zilucoplan)
Others Department of Health and Social Care
  NHS England
Patient carer groups Muscular Dystrophy UK
  Myaware
Professional groups Association of British Neurologists
  Royal College of Physicians
Comparator companies Accord UK – CAU not returned, not participating
  Advanz pharma – CAU not returned, not participating
  Alexion Pharma (ravulizumab)
  Alliance pharmaceuticals – CAU not returned, not participating
  Argenx (efgartigimod)
  Aspen – CAU not returned, not participating
  Bio Products Laboratory – CAU not returned, not participating
  Biotest UK – CAU not returned, not participating
  Cipla EU – CAU not returned, not participating
  CSL Behring UK – CAU not returned, not participating
  Dexcel Pharma – CAU not returned, not participating
  Ennogen Pharma – CAU not returned, not participating
  Grifols UK – CAU not returned, not participating
  Healthcare pharma – CAU not returned, not participating
  Hospira UK – CAU not returned, not participating
  Medac GmBH – CAU not returned, not participating
  Mylan – CAU not returned, not participating
  Napp Pharmaceutical – CAU not returned, not participating
  Nordic Pharma – CAU not returned, not participating
  Nova laboratories – CAU not returned, not participating
  Novartis – CAU not returned, not participating
  Octapharma – CAU not returned, not participating
  Orion Pharma – CAU not returned, not participating
  Pfizer – CAU not returned, not participating
  Roche – CAU not returned, not participating
  Sandoz – CAU not returned, not participating
  Teva UK – CAU not returned, not participating
  Tillomed laboratories – CAU not returned, not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
  Welsh Government

Timeline

Key events during the development of the guidance:

Date Update
23 April 2024 This appraisal will now be discussed at the Committee B meeting on 13 June 2024.
28 September 2023 Invitation to participate
30 June 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late September 2023 when we will write to stakeholders about how they can get involved.
23 March 2023 - 24 April 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4008
23 March 2023 In progress. Scoping commencing
20 July 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual